IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

PHASE2RecruitingINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

September 13, 2022

Primary Completion Date

September 30, 2027

Study Completion Date

June 30, 2029

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Azacitidine

Given IV or SC

PROCEDURE

Biopsy

Undergo biopsy of the bone marrow

DRUG

Enasidenib

Given PO

DRUG

Ivosidenib

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus